Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Supranuclear Palsy, Progressive

• AMX0035 and Progressive Supranuclear Palsy
• GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
• Test-retest Study With [18F]PI-2620 in PSP-RS and NDC
• Evaluation of [18F]APN-1607 as a PET Biomarker
• A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
• RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY
• Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
• Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity
• A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
• Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
• Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks
• A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
• A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
• Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
• Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)
• A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP
• Tau Imaging With JNJ067
• Trial of Parkinson's And Zoledronic Acid
• 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls
• Phase 1 Test-retest Evaluation of [18F]MNI-958 PET
• Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism
• Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
• An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
• Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
• Study of BIIB092 in Participants With Progressive Supranuclear Palsy
• Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
• A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
• Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy
• Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
• A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
• Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
• Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
• Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
• A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
• 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism
• Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
• Safety Study of TPI-287 to Treat CBS and PSP
• Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
• Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy
• Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy
• Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
• Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
• Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
• A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration
• Effects of Coenzyme Q10 in PSP and CBD
• Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy
• Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)
• Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
• Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy
• Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
• Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy
• Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy